clinical trial · NCT06855771
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Bristol-Myers Squibb·phase2·recruiting·n = 130
Carcinoma, Non-Small-Cell LungBMS-986504
brief summary
The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.
started
Sep 9, 2025
primary completion
Dec 29, 2028
completion
Dec 30, 2031
last updated
Apr 23, 2026
official title
A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion After Progression on Prior Therapies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol